Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.64 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18761864 | 0.99 | BTK (0.63) | BTKSYKJAK2JAK1TYK2 | |
| SCHEMBL18761801 | 0.85 | BTK (0.65) | BTKSYKJAK2JAK1TYK2 | |
| SCHEMBL20957612 | 0.84 | BTK (0.69) | BTKSYKCDK4CCND1 | |
| SCHEMBL17199623 | 0.82 | BTK (0.70) | BTKJAK2JAK1JAK3 | |
| SCHEMBL20990507 | 0.82 | BTK (0.66) | BTKSYKJAK2JAK1TYK2 | |
| SCHEMBL17199622 | 0.82 | BTK (0.70) | BTKJAK2JAK1JAK3 | |
| SCHEMBL17187749 | 0.82 | BTK (0.70) | BTKJAK2JAK1JAK3 | |
| SCHEMBL18781581 | 0.82 | BTK (0.70) | BTKJAK2JAK1JAK3 | |
| SCHEMBL17199548 | 0.81 | BTK (0.60) | BTKSYKJAK2JAK1TYK2 | |
| SCHEMBL17187751 | 0.79 | BTK (0.59) | BTKSYKJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10280184-B2 | Heterocyclic kinase inhibitors | ABBVIE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2015158283-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280184-B2 | Heterocyclic kinase inhibitors | MAP3K1, MAP3K20, MAP3K19 | BTK 78/4885SYK 482/4885JAK2 41/4885 |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | BTK 78/4885SYK 482/4885JAK2 41/4885 |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | BTK 81/4885SYK 486/4885JAK2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.